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MiTF Regulates Cellular Response to Reactive Oxygen
Species through Transcriptional Regulation of
APE-1/Ref-1
Feng Liu1,2, Yan Fu3 and Frank L. Meyskens Jr1,2
Microphthalmia-associated transcription factor (MiTF) is a key transcription factor for melanocyte lineage
survival. Most previous work on this gene has been focused on its role in development. A role in carcinogenesis
has emerged recently, but the mechanism is unclear. We classified melanoma cells into MiTF-positive and
-negative groups and explored the function of MiTF in regulating cellular responses to reactive oxygen species
(ROS). The MiTF-positive melanoma cell lines accumulated high levels of apurinic/apyrimidinic endonuclease
(APE-1/Ref-1, redox effector-1), a key redox sensor and DNA endonuclease critical for oxidative DNA damage
repair. We demonstrate that APE-1 is a transcriptional target for MiTF. Knocking down MiTF led to reduced APE-1
protein accumulation, as well as abolished induction of APE-1 by ROS. MiTF-negative melanoma cells survived
more poorly under ROS stress than the MiTF-positive cells based on 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay and Trypan blue staining. Overexpression of APE-1 partially rescued ROS-
induced cell death when MiTF was depleted. We conclude that MiTF regulates cellular response to ROS by
regulation of APE-1, and this may provide a mechanism of how MiTF is involved in melanoma carcinogenesis.
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INTRODUCTION
Much evidence supports the notion that MiTF is the master
control gene for melanocyte lineage survival. Mutations of
the MiTF gene in mice cause a microphthalmia phenotype,
deafness, and lack of pigmentation (Steingrimsson et al.,
2004). Mutations of MiTF in humans cause Waardenburg
syndrome type IIA in which patients exhibit deafness and
pigment disturbances because of a lack of melanocytes
(Tassabehji et al., 1994). The MiTF melanocytes survival
pathway involves a number of genes including Pax3, c-Kit,
Sox9, Sox10, LEF1, and Bcl2 (Levy et al., 2006), among
which Bcl2 is a downstream transcriptional target of MiTF,
whereas others are upstream regulatory factors.
The role of MiTF in differentiation and development is
well established, but evidence of its role in tumorigenesis
remains contradictory. In human melanocytes transfected
with mutant BRAF, overexpression of MiTF leads to
transformation (Garraway et al., 2005). As the MiTF gene is
amplified in some melanomas, it has been suggested that
MiTF can function as a melanoma oncogene (Levy et al.,
2006). In another report, however, MiTF was downregulated
in Braf-transformed murine melanocytes and BRAF-expres-
sing human melanocytes; reexpression of MiTF in these cells
inhibited cell proliferation (Wellbrock and Marais, 2005).
This is consistent with the role of MiTF in cell-cycle exit by
activating p21 and p16ink4A (Carreira et al., 2005; Loercher
et al., 2005). These contradictions have been elegantly
reconciled in a recent review that has pointed out that an
optimal amount of MiTF is required for maintaining
proliferation and differentiation, whereas MiTF levels that
are too low or too high may cause cell-cycle arrest and
apoptosis (Gray-Schopfer et al., 2007).
It is unknown whether MiTF is directly involved in
response to elevated ROS in melanocytes or melanoma cells.
As a transcription factor, a number of downstream targets of
MiTF have been identified. Most of these targets are
melanogenesis proteins such as tyrosinase, TYRP-1, Dct,
Silver, Mc1R, MLANA, and Aim1 (Vance and Goding, 2004).
Recently Hif1a, a well-studied hypoxia response factor, was
identified as a MiTF transcriptional target (Busca et al., 2005).
It is well known that persistent oxidative stress has a key
role in many cancer types, including melanoma (Meyskens
et al., 2001; Sander et al., 2004; Gidanian et al., 2008).
Several factors contribute to elevated ROS level in melanoma
cells. During melanogenesis, hydrogen peroxide is generated
by autooxidation of eumelanin precursors, 6-dihydroxyindole
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and 5,6-dihydroxyindole-2-carboxylic acid (Nappi and Vass,
1996). Melanoma cells also contain strikingly malformed
melanosomes (Farmer et al., 2003; Vachtenheim and
Borovansky, 2004), which leads to leaking of oxidative
quinone and semiquinone intermediates required for melanin
synthesis. Under the oxidative environment, the normal
antioxidative melanin can be oxidized and becomes a
prooxidative ROS generator (Meyskens et al., 2001; Farmer
et al., 2003). Overall, melanoma cells exhibit aberrant redox
regulation as compared to normal human melanocytes
(Meyskens et al., 1997, 2007).
ROS can be detoxified by a number of mechanisms,
including the cellular antioxidative system involving glu-
tathione, thioredoxin, catalase, superoxide dismutase, and
glutathione peroxidase (McEligot et al., 2005). These factors
and proteins are regulated by redox sensors and transcription
factors, among which a multifunctional protein, apurinic/
apyrimidinic endonuclease (APE-1/Ref-1), has an important
role (Evans and Smith, 1997). APE-1 has two essential well-
characterized functions: a DNA endonuclease that can
recognize and cut DNA at the abasic sites and therefore
has a key role in the base excision DNA repair pathway
(Demple and Sung, 2005), and a redox sensor that enhances
the DNA binding activities of a large number of transcription
factors, including p53, Hif1a, AP-1, and nuclear factor-kB
upon an increase of intracellular ROS (Evans and Smith,
1997; Yang et al., 2005). Depletion of APE-1 by siRNA leads
to apoptosis in human cells due to accumulation of damaged
DNA, especially when ROS increases (Fung and Demple,
2005; Yang et al., 2007). APE-1 expression is upregulated at
both mRNA and protein level with increased ROS (Ramana
et al., 1998), but the mechanism of this upregulation is not
fully understood (Evans and Smith, 1997).
In the current study, we explored the function of MiTF in
regulating cellular ROS in normal human melanocytes and
human melanoma cell lines. We demonstrated that APE-1 is a
transcriptional target for MiTF, which activates its basal level
transcription as well as enhances its stimulation by ROS.
As a consequence, MiTF-negative melanoma cells accumu-
lated less APE-1 and lacked an induction of this protein by
ROS, leading to poorer survival as compared to MiTF-positive
cells.
RESULTS
APE-1 is a transcriptional target for MiTF
To search for additional MiTF transcriptional targets, a
genome-wide promoter screening was performed using
E-boxes (CANNTG) and M-box sequences (Aksan and Goding,
1998) as the MITF binding motif according to Xie et al.
(2005). Three E-boxes were found on the APE-1 promoter
region, located at10, þ 52, and þ73, respectively (Figure 1a).
The numbers of the nucleotide sequence are based on APE-1
cDNA (GenBank accession no. NM_001641) and its genomic
DNA, chromosome 14 genomic contig (GenBank accession
no. NT_026437). To confirm MiTF can bind to APE-1
promoter, a chromatin immunoprecipitation analysis was
performed using MiTF antibody. MiTF protein was found on
the APE-1 promoter in SK-Mel-28 cells, whereas MEK1, an
MAPK pathway kinase, which served as a negative control,
did not bind to the APE-1 promoter. MiTF did not bind to the
a-tubulin coding sequence, suggesting that the MiTF binding
to APE-1 promoter is specific (Figure 1b). When a reporter
construct of pAPE-Luc was co-transfected into MiTF-negative
Lu1205 cells with MiTF expression construct pcDNA-MiTF
(Molina et al., 2005), the APE-1 promoter activity increased
3- to 4-fold in the presence of MiTF as compared to
pcDNA3.1 empty vector (Figure 1c). When MiTF was
knocked down in MiTF-positive SK-Mel-28 cells by DNA-
based short hairpin RNA (shRNA) constructs pTER-mi3 or
pTER-mi5 (two different shRNAs, both targeting all isoforms
of MiTF), the APE-1 promoter activity decreased about 50%
(Figure 1d, lanes 3 and 4), which did not occur in cells co-
transfected with pTER-GFPi control construct (Figure 1d, lane
2). As shown in Figure 1d top right corner, pTER-mi3 and
pTER-mi5 knocked down MiTF efficiently, whereas pTER-
GFPi did not alter MiTF accumulation. Furthermore, a
dominant-negative MiTF (Miller et al., 2004) repressed APE-
1 promoter activity in SK-Mel-28 cells (Figure 1e).
MiTF regulates APE-1 promoter activity through E-boxes
To investigate whether the MiTF regulation of APE-1 is
directly through E-boxes on APE-1 promoter, the first E box (at
10 position) was deleted to generate pD1E-Luc construct.
The mutant D1E APE-1 promoter activity decreased to about
half that of wild-type promoter (Figure 1f, lanes 1 and 3).
More importantly, this mutation abolished most of the
induction of APE-1 promoter activity by MiTF (Figure 1f,
lanes 1 though 4). The wild-type APE-1 promoter increased
3- to 4-fold in the presence of MiTF, whereas the D1E
promoter increased only about 20%. Deletion of all three E
boxes reduced the promoter activity to only about 10% of the
wild type, and completely eliminated the activation by MiTF
(Figure 1f, lanes 5 and 6). As deletion of all three E boxes also
deleted transcription initiation sites and part of the
50 untranslated region, the decrease of APE-1 promoter activity
may not be the direct effect of E box mutation. To further
investigate which E box is critical for MiTF regulation, we
made point mutations of each E boxes, designated as E1, E2,
and E3 promoters corresponding to the mutated first, second,
and third E box. These promoters were transfected into A375
melanoma cells with MiTF construct or the empty vector as
control. Again we observed nearly four-fold of induction by
MiTF in wild-type promoter, no induction at all on E1
promoter, about 1.4-fold of induction of E2 promoter, and
about 2.3-fold of induction of E3 promoter (Figure1g). These
results suggest that the first E box (E1) is critical for MiTF
regulation of APE-1 promoter. The second E box also
participates in this regulation, and the third E box is less
critical.
APE-1 protein levels are correlated with MiTF-M protein levels
To examine whether the accumulation levels of APE-1
protein in melanoma cells are correlated with MiTF protein
levels, we knocked down MiTF in melanoma MNT1 cells by
infection of adenovirus carrying shRNA (Ad-shMiTF). Ade-
novirus is used because MNT1 is very difficult to transfect,
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various transfection methods were tested and no more than
10% of transfection efficiency was achieved. As shown in
Figure 2a, MiTF protein levels decreased 48 hours after
infection, and more dramatically after 72 and 96 hours. Both
MiTF bands were diminished simultaneously. The shRNA
degrades mRNA and therefore inhibits newly synthesized
nonphosphorylated MiTF. When this MiTF form decreases,
the corresponding phosphorylated MiTF may also decrease
due to less substrate for its kinase(s). The APE-1 protein level
decreased concomitantly. As a control, MiTF and APE-1
protein level remained unchanged in cells infected with
adenovirus carrying luciferase shRNA (Ad-shLuc) (Figure 2a).
We further examined the protein accumulation of MiTF and
APE-1 levels in normal human melanocytes and melanoma
cell lines. Of the eight melanoma cell lines examined, five
were MiTF negative, in which all isoforms of MiTF protein
were undetectable using 80 mg of input total protein. These
were cell lines c8161, c81-46A, WM3211, Lu1205, and
A375 (Figure 2b). Three melanoma cell lines, SK-Mel-28,
MNT1, and c83-2C, were MiTF positive. In addition to the
MiTF-M isoforms, all these latter cells also accumulated
MiTF-A isoform (Figure 2b). Normal human melanocytes
accumulate mainly the MiTF-M isoform, the MiTF-A isoform
is barely detectable (Figure 2b). Hereafter MiTF is referred to
as MiTF-M isoform in this paper because this is the main
isoform expressed and observed in melanoma and melano-
cytes. APE-1 accumulation level is correlated to that of MiTF
protein level in normal melanocytes and melanoma cell
lines. APE-1 accumulation from the western blot was
quantitated by a densitometer and normalized to that of a-
tubulin (Figure 2c). The APE-1 accumulation in normal
melanocytes is defined as 1. The average APE-1 of five MiTF-
negative cells was 0.74, and the average APE-1 level of three
MiTF-positive melanoma cells was 1.37 (P¼ 0.046, o0.05).
This comparative data suggest that MiTF levels in melanoma
cells are correlated with APE-1 levels. To further demonstrate
that APE-1 level is correlated to MiTF level, normal human
melanocytes were precultured in media with no 12-O-
tetradecanoylphorbol-13-acetate and low bovine pituitary
extract (0.03%) for 24 hours, cells were then treated with
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Figure 1. APE-1 is a transcriptional target for MiTF. (a) The APE-1 promoter and gene structure. nCaRE, binding site for negative calcium response elements; Sox
site, SOX transcription factor binding site; cAMP response element-binding protein, cAMP response element binding site; E2F site, E2F binding site; E-box,
consensus MiTF binding site; ATG, translation initiation site; 30 UTR, 30 untranslated region. (b) MiTF binds to APE-1 promoter. Chromatin immunoprecipitation
was performed using SK-Mel-28 cells and anti-Mek1 or anti-MiTF antibodies. The precipitated chromatin was PCR amplified with either APE-1 promoter-
specific primers (top) or a-tubulin primers (bottom). (c) MiTF activates APE-1 promoter activity. pAPE1-Luc reporter construct was co-transfected with MiTF
expression plasmid into Lu1205 cells, luciferase activities were assayed 48 hours after transfection and normalized by b-galatosidase activity (pCH110) that is
also co-transfected. (d) knockdown of MiTF in Sk-Mel-28 cells decreased APE-1 promoter activity. pAPE-Luc reporter construct was co-transfected with MiTF
shRNA plasmids pTER-mi3 or pTER-mi5 or control plasmid pTER-GFPi that carries shRNA targeting GFP. Luciferase activity was assayed 48 hours after
transfection. Western blot in the top right corner indicates the MiTF level (top) and a-tubulin level from cells in lanes 2, 3, and 4. (e) A dominant-negative MiTF
protein inhibited APE-1 promoter activity in SK-Mel-28 cells. At 12 hours after transfection with the APE-1 wild-type promoter, cells were infected with
adenovirus expressing a control nonsense polypeptide (PolyP), wild-type MiTF (MiTF-WT) or dominant-negative MiTF (MiTF-DN) (Miller et al., 2004). Luciferase
activities were measured 48 hours after transfection. Cells transfected but not infected with any virus were used as a control (uninfected). (f) MiTF regulates APE-
1 promoter activity through E-boxes. Mutant APE-1 promoters lacking the first E box (pD1E-Luc) or all three E boxes (pD3E-Luc) were analyzed as above along
with the wild-type APE-1 promoter in A375 cells. (g) The first E box is critical for MiTF regulation. Site mutagenesis was performed to make point-mutated
promoters, which were used for activity analysis in the presence or absence of MiTF construct. The data were normalized to co-transfected b-galactosidase
activity and the induction fold of each promoter was calculated by comparing activity in the presence of MiTF to that in the absence of MiTF.
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a-MSH. Addition of a-MSH induced MiTF accumulation after
6 and 12 hours, which was also correlated to an increase of
APE-1 accumulation under such condition (Figure 2d).
MiTF phosphorylation after ROS elevation is correlated to
increased APE-1 protein level
APE-1 is a key protein for redox sensing, and its association
with MiTF suggests that MiTF itself may be involved in
regulating cellular ROS response. Next, we treated SK-Mel-
28 cells with 0.1mM H2O2 to elevate cellular ROS levels. The
MiTF protein was phosphorylated 1 hour after treatment and
increased slightly from 1 to 4 hours, then at 9 to 12 hours
degraded almost completely (Figure 3a). These results are
consistent with a previously published data, which indicated
that MiTF degrades with an increase of cellular ROS level
(Jimenez-Cervantes et al., 2001). However, the status of
phosphorylation of MiTF was not previously reported. When
cells were treated with U0126, an Mek1/2-Erk1/2 kinase
inhibitor, before exposure to ROS, the upper band was not
enhanced as compared to cells without the inhibitor (Figure
S1), suggesting this band represents phosphor-MiTF, and the
phosphorylation is via Erk1/2 mitogen-activated protein
kinase pathway. To confirm this phosphorylation of MiTF is
a particular response to elevated cellular ROS levels, we then
treated c83-2C cells with glucose oxidase (GOX, 100
mUml1), which reacts with glucose and oxygen to produce
constant low level of H2O2, and examined the response of
MiTF and APE-1. As shown in Figure 3b, at time 0 when cells
were treated with GOX for 1 hour MiTF accumulation level
increased slightly and the phosphorylated form also increased
as compared to the untreated cells (lanes 1 and 2). Again the
MiTF protein degraded 9–12 hours after GOX treatment, and
then recovered to its original untreated level 16 hours after
treatment. Interestingly, protein accumulation of APE-1
increased after GOX treatment and remained elevated during
the time course as compared to that in the untreated cells. It
seemed that APE-1 levels reached its peak 3–6 hours after
recovering from GOX treatment, following the elevated
phosphor-MiTF protein level (Figure 3b, bottom). The kinetics
of phosphor-MiTF and APE-1 was similar during the first 9
hours of recovering. A similar response of MiTF and APE-1
accumulation was also observed in normal human melano-
cytes after 0.1mM of H2O2 treatment (Figure 3c), with a
slightly different kinetics over the time course. MiTF-M was
phosphorylated 1 hour after H2O2 treatment, decreased after
4–6 hours, and recovered 9–24 hours after the treatment
(Figure 3c). The APE-1 protein accumulation increased 2–4
hours after treatment and remained elevated until 16 hours,
then returned to its pretreatment level (Figure 3c).
MiTF is required for the upregulation of APE-1 after elevated
ROS
As seen in Figure 2b, although the APE-1 protein accumulates
to a lower level in MiTF-negative melanoma cell lines c8161,
c81-46A, WM3211, Lu1205, and A375, as compared to
MiTF-positive normal melanocytes and melanoma SK-Mel-
28, MNT1, and c83-2C, the APE-1 level did not diminish in
the MiTF-negative cell lines. This suggests that the basal level
expression of APE-1 does not require MiTF, although MiTF
can activate Ape-1 promoter. Therefore we next examined
whether MiTF was required for upregulation of APE-1 upon
H2O2 treatment. The APE-1 response to H2O2 treatment in
MiTF-negative cell lines A375 and c81-46A were examined
(Figure 3d, top and bottom). In both cell lines, APE-1 did not
exhibit a significant increase after treatment with 0.15mM
H2O2. In contrast, JunB, one of the AP1 proteins that usually
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Figure 2. APE-1 protein level is correlated with that of MiTF. (a) Knockdown of MiTF led to a decrease in APE-1 protein accumulation. MNT1 cells were
infected with Ad-shMiTF or Ad-shLuc and collected for western blot analysis at the indicated days. (b) Western blot analysis of MiTF and APE-1 accumulation
in normal human melanocytes and melanoma cell lines: (1) Normal human melanocytes, (2) c8161, (3) c81-46A, (4) WM3211, (5) Lu1205, (6) A375,
(7) SK-Mel-28, (8) MNT1, and (9) c83-2C. a-Tubulin serves as a loading control. Numbers below the western blot indicate the quantitated relative APE-1 levels
(see c). (c) Quantitative analysis of APE-1 accumulation levels based on (b). The western results were quantitated by a densitometer and APE-1 level is
normalized to a-tubulin. Normalized APE-1 accumulation in normal human melanocytes was defined as 1.0 and its levels in other cell lines were relative to
normal human melanocytes. (d) APE-1 protein level is correlated to MiTF upregulation by a-MSH. Normal human melanocytes were cultured in media without
12-O-tetradecanoylphorbol-13-acetate and reduced bovine pituitary extract levels for 24 hours (lane 1), a-MSH was then added and cells were collected at
6 and 12 hours (lanes 2 and 3) for western blot analysis.
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respond to increased cellular ROS levels, increased 3 hours
after the treatment and reached its highest level at 6–9 hours
(Figure 3d).
To investigate whether APE-1 promoter responded to MiTF
levels after H2O2 treatment, pAPE-Luc was co-transfected
with one of the following constructs: pcDNA3.1, pcDNA-
MiTF, pTER-GFPi, and pTER-mi3. After 36 hours, cells were
treated with 0.15mM H2O2 and collected for luciferase assay
12 hours later. As shown in Figure 3e, again overexpression
of MiTF increased APE-1 promoter activity (open box, lanes 1
and 2), whereas depletion of MiTF by shRNA decreased APE-
1 activity (open box, lane 3 and 4). When treated with H2O2,
APE-1 promoter activity increased in cells transfected with
pcDNA3.1, pcDNA-MiTF, and pTER-GFPi, where MiTF is
present (lanes 1–6). APE-1 promoter activity was not
stimulated by H2O2 when MiTF was depleted by pTER-mi3
(lanes 7–8), suggesting that MiTF is required for this
stimulation. Comparing cells transfected with pcDNA3.1
alone or pcDNA-MiTF (lanes 2 and 4, filled box), over-
expression of MiTF did not lead to more dramatic induction
of APE-1 after H2O2 treatment, presumably due to saturation
of MiTF on the APE-1 promoter in this cell line. These results
demonstrate that upon H2O2 treatment APE-1 upregulation
requires MiTF.
MiTF-positive cells are more resistant to H2O2-induced cell
death
To examine the cellular effect of MiTF under the elevated
ROS condition, we knocked down MiTF in both SK-Mel-28
and MNT1 human melanoma cells by different approaches.
The plasmid carrying tandem repeats of MiTF shRNA pTER-
mi3 was transfected into SK-Mel-28 cells, whereas the same
vector carrying GFP shRNA was used as control. No obvious
cell death or growth arrest was observed up to 4 days after
transfection. As examined by western blot analysis, MiTF
levels decreased significantly 24 hours after transfection with
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Figure 3. MiTF is phosphorylated and required for APE-1 induction after ROS treatment. (a) Western blot analysis of MiTF in SK-Mel-28 cells after H2O2
treatment. The Sk-Mel-28 cells were treated with 0.1mM H2O2 and collected for western blot analysis at the indicated time points. p84 serves as a loading
control. (b) MiTF and APE-1 accumulation in c83-2C cells after GOX (150mUml1) treatment. Cells were incubated with GOX for 1 hour, washed with
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(d) Western blot analysis of APE-1 accumulation in two MiTF-negative melanoma cells A375 (top) and c81-46A (bottom) after 0.15mM H2O2 treatment.
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assayed 48 hours after transfection.
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pTER-mi3, and maintained a low level until 96 hours post
transfection (Figure 4a). Cells transfected with control GFP
shRNA did not show changes in MiTF levels (Figure 4a). APE-1
protein level also decreased when MiTF was knocked
down, but not depleted (Figure 4a). These transfected cells
were treated with H2O2 and collected for western blot
analysis. APE-1 protein level remained constant after H2O2
treatment (Figure 4b), whereas JunB induction was obvious
3–12 hours after treatment. However, an induction of APE-1
protein was observed in SK-Mel-28 cells with no shRNA
transfection 6–12 hours after H2O2 treatment (Figure 4c).
These results indicated that MiTF not only activated the basal
level of APE-1, it also regulated the induction of APE-1 by
ROS stress.
APE-1 is a critical protein for redox sensing and DNA
damage repair (Evans and Smith, 1997), therefore it is
important for cell survival. To examine the consequence of
MiTF regulation on APE-1, SK-Mel-28 cells was first
transfected with pTER-GFPi or pTER-mi3, and then treated
with 0.1 or 0.15mM H2O2. Cell proliferation was assayed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide method and cell death was assayed by Trypan blue
staining. As shown in Figure 4d (left panel), cell viability
decreased more dramatically when MiTF was knocked down.
For example, after treatment with 0.15mM H2O2, cell
viability decreased to 45% for those transfected with GFP
shRNA as compared to the untreated cells, whereas viability
decreased to about 10% for those with MiTF knocked down
(Figure 4d, left panel, lane 3). Meanwhile, the percentages of
cell death in GFP shRNA- and pTER-mi3-transfected cells
were both about 8.5% without treatment; this rate increased
to 15% in vector-transfected cells, and to 38% in MiTF-
knockdown cells after 0.15mM H2O2 treatment (Figure 4d,
right panel, lane 3). This observation was repeated in MNT1
cells when MiTF was knocked down by adenovirus carrying
an shRNA targeting to a different area in MiTF mRNA. This
method depleted MiTF 72 hours after infection (Figure 2a). As
shown in Figures 4e and f, after various dosage of H2O2 or
GOX treatment, MNT1 cells exhibited more cell death when
cells were depleted of MiTF and under ROS stress.
Overexpression of APE-1 partially rescued the MiTF-mediated
H2O2-induced cell death
Previously our laboratory demonstrated that overexpression
of APE-1 protected melanoma cells from H2O2-induced cell
death (Yang et al., 2005). To further demonstrate that the
enhanced H2O2-induced cell death in MiTF-depleted cells is
mediated by APE-1, we overexpressed flag-tagged APE-1 in
SK-MEL-28 cells, whereas MiTF was knocked down, and then
examined the cell proliferation and cell-death rate after H2O2
treatment. As shown in Figure 5a, 60 hours after transfection
of pFlag-APE-1 and 48 hours after infection with Ad-shMiTF,
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MiTF protein level decreased dramatically, as did the
endogenous APE-1 protein level (Figure 5a, lane 3). Over-
expression of flag-APE-1 slightly rescued viability after GOX
or H2O2 treatment (Figure 5b, rows 1 and 3). Knocking down
MiTF without APE-1 overexpression led to a poorer viability
(Figure 5b, comparing rows 1 and 2), and expression of flag-
APE-1 increase viability in these cells (rows 2 and 4).
DISCUSSION
In this study we investigated the role of MiTF in response to a
moderate increase of intracellular ROS. We have demon-
strated that APE-1 is a transcriptional target for MiTF, and that
MiTF regulates cellular ROS response by upregulating APE-1.
Interestingly, the MiTF-positive melanoma cells accumulated
relatively higher levels of APE-1 than MiTF-negative cells.
This increased APE-1 protein level may reflect an increased
APE-1 activity, therefore it is not surprised that the MiTF-
positive melanoma cells were more resistant to H2O2-
induced cell death and exhibited better survival as compared
to MiTF-negative cells. Currently there is a substantial effort
directed toward developing chemoprevention agents against
cancers, including melanoma, based on their elevated ROS
levels (Meyskens et al., 2001; Cen et al., 2002). For example,
cells treated with buthionine sulfoximine, an inhibitor of
g-glutamyl-cysteine synthetase, exhibited lower cellular
glutathione level and therefore higher level of ROS (Fruehauf
et al., 1997). In melanoma cells, the endogenous cellular
ROS level is relatively high; when these cells are treated with
drugs such as buthionine sulfoximine, they have an even
higher level of ROS, which leads to apoptosis (Fruehauf et al.,
1997). Our finding that MiTF-positive melanoma cells are
more resistant to H2O2-induced cell death suggests that the
therapeutic approach by increasing cellular ROS may be
more effective in MiTF-negative melanoma than in MiTF-
positive ones, and therefore it may be necessary to
characterize each melanoma based on its MiTF levels to
maximize the therapeutic approach. We examined 11
primary melanoma tissues by immunohistochemistry, our
preliminary data indicated that 2 out of 11 samples are MiTF-
positive and 9 are MiTF-negative (F Liu and FL Meyskens,
unpublished data), giving more weights on seeking an MiTF-
based differential treatment approach.
Several lines of evidence support our conclusion that APE-
1 is a downstream transcriptional target for MiTF: (1) three
E boxes were found on the APE-1 promoter, (2) the MiTF
protein directly binds to APE-1 promoter through the E-boxes,
(3) MiTF-positive cell lines accumulate higher level of APE-1
protein, and (4) induction of APE-1 by ROS requires MiTF.
Factors required for APE-1 upregulation upon H2O2 treatment
are not fully understood. It has been reported that the cAMP
response element on APE-1 promoter (Figure 1a) is required
for APE-1 upregulation upon H2O2 treatment, inferring that
the cAMP response element-binding protein was also
required (Grosch and Kaina, 1999). Interestingly, APE-1 has
been shown to interact with cAMP response element-binding
protein and activate Hif1a and its own expression. All of
these proteins form a transcription activation complex to
activate VEGF under hypoxia conditions (Ramphal et al.,
2006). cAMP response element-binding protein binds p300
or CBP to modify chromatin structure for transcription
activation (Rouaux et al., 2004). MiTF binds DNA through
its basic helix-loop-helix domain and activates transcription
in both p300-dependent and -independent manners (Sato
et al., 1997; Vachtenheim et al., 2007). In the current study
MiTF was phosphorylated in both melanoma cells and
normal melanocytes after elevated ROS treatment (Figures
3a–c), suggesting that MiTF itself is responsive to cellular ROS
change. Hif1a, another key transcription factor involved in
hypoxia-induced VEGF activation, is also a transcription
target for MiTF (Busca et al., 2005). Both APE-1 and Hif1a
have key roles in response to cellular ROS stress. The fact that
both genes are MiTF transcriptional targets suggests that MiTF
regulates a broad range of gene expressions in response to
ROS stimuli.
In response to ROS stimulation, MiTF was phosphorylated
and then degraded (Figures 3a–c). This observation is
consistent with previous reports that dual phosphorylation
of MiTF leads to transient activation and subsequent
degradation of MiTF (Wu et al., 2000). The phosphorylation
of MiTF upon H2O2 treatment can be inhibited by Mek1
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inhibitor U0126 (Figure S1), suggesting that the phosphoryla-
tion of MiTF is mediated by MAPK-Erk1/2 pathway, likely on
serine 73 (Wu et al., 2000; Molina et al., 2005). This
phosphorylation is probably important for activating Ape-1
transcription after ROS stress.
In summary, here we show evidence that MiTF is involved
in regulating the cellular stress response. This study also
provides an alternative explanation for the role of MiTF in
melanoma carcinogenesis by regulating cellular ROS re-
sponse: loss of MiTF at an early stage may lead to reduced
APE-1 and therefore persistent high level of ROS. However, at
later stages of transformation, MiTF accumulation may lead
to increased APE-1 and other survival factors such as Bcl2,
which in turn leads to better survival outcomes for some cells.
We note that all three MiTF-positive melanoma cell lines
were derived from malignant metastatic melanomas, whereas
the others were obtained from various earlier stages of
melanoma. This is consistent with clinical reports that high
level of MiTF in blood samples was correlated with poor
outcome of patients with melanoma (Koyanagi et al., 2006),
as well as the fact that low levels of MiTF promotes
invasiveness, whereas high level promotes proliferation
(Carreira et al., 2006).
MATERIALS AND METHODS
Cell lines and cell culture
Normal human melanocytes isolated from newborn foreskin from
circumcision surgery followed the procedure by Eisinger and Marko
(1982), and cultured in MCDB153 medium supplied with 2% fetal
bovine serum, 10 ngml1 of 12-O-tetradecanoylphorbol-13-acetate
and 0.15% of bovine pituitary extract unless otherwise stated (Yang
et al., 2005). The medical ethnical committee of University of
California Irvine approved all described studies. The study was
conducted according to the Declaration of Helsinki Principles.
Patient consent for experiments was not required because US laws
consider human tissue left over from surgery as discarded material.
Melanoma cell lines c8161, c81-46A, and c83-2C were cultured in
F10 media; Lu1205 cells were cultured in L15/MCDB153 (1:1)
media; WM3211 were cultured in RPMI; A375 and MNT1 cells were
cultured in Dulbecco’s modified Eagle’s medium; SK-Mel-28 cells
were cultured in Eagle’s minimal essential medium. All these media
were supplied with 5% fetal bovine serum, 5% newborn bovine
sera, and 2% penicillin and streptomycin, except that MNT1 media
contained doubled concentration of fetal bovine serum and newborn
bovine serum (10% each). All cells were kept at 37 1C in 5% CO2
incubator.
Cell treatment
H2O2 is first diluted in H2O, and then added to media directly at the
desired concentration. GOX was purchased from Sigma (G2133; St
Louis, MO) and prepared according to the manufacturer’s instruc-
tion. GOX was added directly into cell media and incubated for 1
hour. Cells were then washed with 1 phosphate-buffered saline
three times, and returned to incubator with fresh media.
DNA and shRNA constructs
MiTF shRNA expression cassette (mi3) was constructed by inserting a
DNA fragment derived from two annealed synthetic oligos (Table S1)
into pTERþ vector (van de Wetering et al., 2003), with the targeting
sequence on MiTF: 50-GTACCACATACAGCAAGCCCA-30. The
SalI–XhoI fragment containing the H1-shRNA construct was en-
gineered to repeated four times (tandem repeat) in the plasmid pTER-
mi3. The pTER-mi5 construct was made the same way except that
different oligos targeting a different sequence were used (Table S1).
The targeting sequence on MiTF is: 50-GGACAATCACAACCTGATT
GA-30. The shRNA expression cassette from pTER-mi5 was cloned
into pAdTrack (He et al., 1998) for generating adenovirus Ad-
shMiTF. The pTER-GFPi was made the same way using annealed
oligos targeting GFP (Table S1). The Luc-ShRNA adenovirus Ad-
shLuc was reported before (Liu and Lee, 2006). The pcDNA-MiTF is
a gift from Dr Lee Bardwell (University of California, Irvine) (Molina
et al., 2005). The p3xFLAG-APE1 is a gift from Dr Kaikobad Irani
(University of Pittsburgh Medical Center). Adenovirus carrying
nonsense polypeptide (control virus, Adv-polyP), wild-type MiTF
(Adv-MiTF-WT), or dominant-negative MiTF (Adv-MiTF-DN) were
gifts from Dr David Fisher (Dana-Farber Cancer Institute, Children’s
Hospital, Harvard Medical School) (Miller et al., 2004).
Cell viability assay and Trypan blue staining
Cell viability was determined by standard 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay. Cell death was analyzed
by Trypan blue staining. Both attached and floating cells were
collected and incubated with 50% Trypan blue solutions for 5
minutes before blue cells and dye-repelling viable cells were
counted under a microscope.
Cell lysate and western blot analysis
Cell pellet was lyzed in a lysis 250 buffer (Liu and Lee, 2006) and
quantified by the Bradford protein assay method (Bio-Rad, Rich-
mond, CA). Western blot was performed using antibodies against
MiTF C5 plus D5 (MS-773-P; Lab Vision, Fremont, CA), APE-1
(Novus Biologicals, Littleton, CO), p84 (Abcam, Cambridge, MA),
and a-tubulin (T9026; Sigma).
Reporter constructs and luciferase reporter assay
The APE-1 promotor reporter plasmid was constructed by ligating the
pGL3-basic vector (digested with NheI and HindIII) and an
AvrII–HindIII fragment from Ape-1 promoter plasmid pCB2 (Harrison
et al., 1995). The resulting plasmid is termed pAPE1-Luc. Luciferase
activities were measured according to the manufacturer’s (Promega,
Madison, WI) instructions in an ML 3000 Microtiter Plate
Luminometer from Dynatech Laboratories Inc. (Chantilly, VA). The
co-transfected b-galactosidase activities (pCH110) were measured
by a Beckman DU-64 spectrophotometer at 410 nm. The primers
used for making the deletion mutant D1E and D3E, point mutants E1,
E2, and E3 are listed in Table S1. The resulting point mutations for
E1, E2, and E3 are from original E box sequence CACGTG to
GATATC (E1), GTCGAC (E2), and GAATTC (E3).
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were based on the pre-
viously published protocol, with minor modifications (Chakrabarti
et al., 2002; Liu and Lee, 2006). Three 10-cm dishes of cells were
crosslinked with 1% formaldehyde in phosphate-buffered saline for
15 minutes at room temperature, and washed in phosphate-buffered
saline three times. The fixed cells were resuspended in 0.6ml of
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sonication buffer (Liu and Lee, 2006) and sonicated with an
ultrasonic processor (Cole-Parmer 4710 series; Cole-Parmer Instru-
ments Co., Chicago, IL) at 60% amplitude. After 15 cycles of 12-
second sonication pulses, the sheared chromatin was clarified by
centrifugation and incubated with 5 mg of primary antibodies at 4 1C
overnight. Protein A/G-Sepharose slurry (25 mg) was added and
incubated for 1 hour. The Sepharose beads were spun down,
washed, eluted, and precipitated as described before (Liu and Lee,
2006). In total, 1-ml aliquots out of 30-ml DNA were used for PCR.
AT1 and AT2 primers (Table S1) were used for a-tubulin PCR; ref1p4
and ref1p6 (Table S1) were used for amplifying APE-1 promoter. The
PCR was performed for 35 cycles for all samples and primers.
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